ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.65+0.06 (+1.67%)
Close on Nov 17, 2026Market cap $362.98MP/E –Yield –
ARS Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
ARS Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $116.93M, up 4.1% year over year. For fiscal 2025 it was $84.28M, down 5.5% from the year before. The highest annual figure on record is $89.15M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.28M | -5.5% |
| FY2024 | Dec 31, 2024 | $89.15M | +297063.3% |
| FY2023 | Dec 31, 2023 | $30.00K | -97.7% |
| FY2022 | Dec 31, 2022 | $1.32M | -76.1% |
| FY2021 | Dec 31, 2021 | $5.51M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $33.66M | +114.2% |
| Q1 FY2026 | Mar 31, 2026 | $22.68M | +184.5% |
| Q4 FY2025 | Dec 31, 2025 | $28.09M | -67.6% |
| Q3 FY2025 | Sep 30, 2025 | $32.50M | +1471.6% |
| Q2 FY2025 | Jun 30, 2025 | $15.72M | +3043.4% |
| Q1 FY2025 | Mar 31, 2025 | $7.97M | – |
| Q4 FY2024 | Dec 31, 2024 | $86.58M | – |
| Q3 FY2024 | Sep 30, 2024 | $2.07M | – |
| Q2 FY2024 | Jun 30, 2024 | $500.00K | +4900.0% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $10.00K | -97.8% |
| Q1 FY2023 | Mar 31, 2023 | $20.00K | -97.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2022 | Sep 30, 2022 | $189.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $464.00K | – |
| Q1 FY2022 | Mar 31, 2022 | $663.00K | – |
See a number that looks wrong?